Cancer related inflammation: The macrophage connection

Cancer Letters

Volumn 267, Issue 2, 2008, Pages 204-215

  Sica, Antonio ^a   Allavena, Paola ^a   Mantovani, Alberto ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Cancer; Chemokines; Cytokines; Inflammation; Macrophage polarization; Therapeutic targets; Tumor promotion; Tumor associated macrophages

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL TRANSFORMATION; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 47749155653     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.028     Document Type: Review

References (93)

1. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
2. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., et al. Intratumoral T cells recurrence and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
3. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
4. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55 (2006) 451-458
5. Taylor R.C., Patel A., Panageas K.S., Busam K.J., and Brady M.S. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 25 (2007) 869-875
6. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
7. Bingle L., Brown N.J., and Lewis C.E. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J. Pathol. 196 (2002) 254-265
8. An T., Sood U., Pietruk T., Cummings G., Hashimoto K., and Crissman J.D. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma Relation to prognostic parameters. Am. J. Pathol. 128 (1987) 52-60
9. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., and Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14 (2005) 425-431
10. Allavena P., Sica A., Solinas G., Porta C., and Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev. Oncol. Hematol. (2007)
11. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
12. Colombo M.P., and Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 65 (2005) 9113-9116
13. Pollard J.W. Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
14. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., Salmona M., and Mantovani A. Regulation of the macrophage content of neoplasms by chemoattractants. Science 220 (1983) 210-212
15. Mantovani A., Schioppa T., Porta C., Allavena P., and Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25 (2006) 315-322
16. Lewis C., and Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 167 (2005) 627-635
17. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
18. Knowles H.J., and Harris A.L. Macrophages and the hypoxic tumor microenvironment. Front. Biosci. 12 (2007) 4298-4314
19. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., Bernasconi S., Saccani S., Nebuloni M., Vago L., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198 (2003) 1391-1402
20. Mantovani A., Allavena P., and Sica A. Tumor-associated macrophages as a prototypic type II polarised phagocyte population: role in tumor progression. Eur. J. Cancer 40 (2004) 1660-1667
21. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., Bottazzi B., Doni A., Vincenzo B., Pasqualini F., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107 (2006) 2112-2122
22. Mantovani A., Sica A., and Locati M. Macrophage polarization comes of age. Immunity 23 (2005) 344-346
23. Chomarat P., Banchereau J., Davoust J., and Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1 (2000) 510-514
24. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumor-associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42 (2006) 717-727
25. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
26. Mantovani A., Sozzani S., Locati M., Allavena P., and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002) 549-555
27. Mantovani A., Sozzani S., Locati M., Schioppa T., Saccani A., Allavena P., and Sica A. Infiltration of tumors by macrophages and dendritic cells: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found. Symp. 256 (2004) 137-145 discussion, 146-138, 259-169
28. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., and Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol. 14 (2004) 155-160
29. Nowicki A., Szenajch J., Ostrowska G., Wojtowicz A., Wojtowicz K., Kruszewski A.A., Maruszynski M., Aukerman S.L., and Wiktor-Jedrzejczak W. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer 65 (1996) 112-119
30. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001) 727-740
31. Rauh M.J., Ho V., Pereira C., Sham A., Sly L.M., Lam V., Huxham L., Minchinton A.I., Mui A., and Krystal G. SHIP represses the generation of alternatively activated macrophages. Immunity 23 (2005) 361-374
32. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
33. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351 (2004) 2159-2169
34. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., and Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 2645-2650
35. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
36. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
37. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., and Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25 (2006) 387-408
38. Kataki A., Scheid P., Piet M., Marie B., Martinet N., Martinet Y., and Vignaud J.M. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 140 (2002) 320-328
39. Ahmed F., Wyckoff J., Lin E.Y., Wang W., Wang Y., Hennighausen L., Miyazaki J., Jones J., Pollard J.W., Condeelis J.S., et al. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res. 62 (2002) 7166-7169
40. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., Stanley E.R., Segall J.E., and Condeelis J.S. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65 (2005) 5278-5283
41. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
42. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
43. Mantovani A., Bottazzi B., Colotta F., Sozzani S., and Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 13 (1992) 265-270
44. Lewis C.E., Leek R., Harris A., and McGee J.O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol. 57 (1995) 747-751
45. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9 (2003) 789-795
46. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., and Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
47. Venneri M.A., De Palma M., Ponzoni M., Pucci F., Scielzo C., Zonari E., Mazzieri R., Doglioni C., and Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109 (2007) 5276-5285
48. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., and Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161 (2002) 947-956
49. Hotchkiss K.A., Ashton A.W., Klein R.S., Lenzi M.L., Zhu G.H., and Schwartz E.L. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res. 63 (2003) 527-533
50. Coussens L.M., Tinkle C.L., Hanahan D., and Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103 (2000) 481-490
51. Locati M., Deuschle U., Massardi M.L., Martinez F.O., Sironi M., Sozzani S., Bartfai T., and Mantovani A. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 168 (2002) 3557-3562
52. Sangaletti S., Stoppacciaro A., Guiducci C., Torrisi M.R., and Colombo M.P. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J. Exp. Med. 198 (2003) 1475-1485
53. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., and Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164 (2000) 762-767
54. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203 (2006) 871-881
55. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
56. Schutyser E., Struyf S., Proost P., Opdenakker G., Laureys G., Verhasselt B., Peperstraete L., Van de Putte I., Saccani A., Allavena P., et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem. 277 (2002) 24584-24593
57. Bronte V., Serafini P., Mazzoni A., Segal D.M., and Zanovello P. l-Arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24 (2003) 302-306
58. Sica A., and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117 (2007) 1155-1166
59. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201 (2005) 1257-1268
60. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
61. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., Bottazzi B., Colombo M.P., Mantovani A., and Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66 (2006) 11432-11440
62. Torroella-Kouri M., Ma X., Perry G., Ivanova M., Cejas P.J., Owen J.L., Iragavarapu-Charyulu V., and Lopez D.M. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 65 (2005) 10578-10584
63. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117 (2007) 3846-3856
64. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117 (2007) 3988-4002
65. Grivennikov S., and Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 13 (2008) 7-9
66. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
67. Pedranzini L., Leitch A., and Bromberg J. Stat3 is required for the development of skin cancer. J. Clin. Invest. 114 (2004) 619-622
68. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10 (2004) 48-54
69. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., Kammula U.S., Chen Y., Qin L.X., Tang Z.Y., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 (2006) 99-111
70. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
71. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumor promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
72. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007) 1050-1059
73. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2 (2003) 803-811
74. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., and Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13 (1999) 1822-1833
75. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
76. Knowles H., Leek R., and Harris A.L. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found. Symp. 256 (2004) 189-200 discussion 200-184, 259-169
77. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
78. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., and Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
79. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
80. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11 (2005) 992-997
81. Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M., Silberstein S., Stalla G.K., Holsboer F., and Arzt E. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131 (2007) 309-323
82. Van Rooijen N., and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174 (1994) 83-93
83. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., and Schwendener R.A. Clodronate-liposome-mediated depletion of tumor-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006) 272-281
84. Sessa C., De Braud F., Perotti A., Bauer J., Curigliano G., Noberasco C., Zanaboni F., Gianni L., Marsoni S., Jimeno J., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23 (2005) 1867-1874
85. Allavena P., Signorelli M., Chieppa M., Erba E., Bianchi G., Marchesi F., Olimpio C.O., Bonardi C., Garbi A., Lissoni A., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65 (2005) 2964-2971
86. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., and Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 (2005) 3437-3446
87. Sinha P., Clements V.K., and Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005) 636-645
88. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 1269-1274
89. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., and Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005) 312-319
90. Joseph I.B., and Isaacs J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst. 90 (1998) 1648-1653
91. Carta L., Pastorino S., Melillo G., Bosco M.C., Massazza S., and Varesio L. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J. Immunol. 166 (2001) 5374-5380
92. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37
93. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004) 623-633